AAV Transduction Modulators Enhancing Gene Delivery Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies using adeno-associated virus (AAV) vectors face challenges in modulating transduction efficiency, which is essential for effective delivery of therapeutic payloads across various therapeutic areas.
Innovation Solution
The use of AAV transduction modulators that target specific genes or gene products associated with increased or decreased transduction efficiency, such as AAV-R, GPR108, WDR11, or MRE11, to alter the expression, activity, or stability of these molecules, thereby enhancing or reducing the transduction efficiency of AAV particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV vectors are used for gene therapy delivery, then therapeutic payloads can be delivered to target cells, but transduction efficiency is insufficient for effective delivery across various therapeutic areas
Solution Approach 1:
The patent uses host cell proteins (HCPs) such as AAV-R, GPR108, WDR11, and MRE11 as intermediary molecules to mediate the interaction between AAV vectors and target cells. By modulating the expression levels of these HCPs, the patent enhances transduction efficiency without directly modifying the AAV vector structure, thereby resolving the contradiction between delivery capability and transduction efficiency.
Solution Approach 2:
The patent changes the expression parameters (levels) of specific host cell proteins to optimize AAV transduction. By upregulating or downregulating HCP expression in target tissues, the patent achieves enhanced transduction efficiency and delivery effectiveness, directly addressing the technical contradiction through parameter optimization rather than structural modification.
2Productivity
If transduction efficiency is increased to improve therapeutic delivery, then delivery effectiveness improves, but specificity to target tissues may be compromised
Solution Approach 1:
The patent applies local quality by targeting specific host cell proteins that are preferentially expressed in particular tissues. For example, AAV-R is enriched in the brain while MRE11 is enriched in the liver. By modulating tissue-specific HCP expression, the patent achieves enhanced transduction efficiency while maintaining or improving tissue specificity, resolving the contradiction between productivity and adaptability.
Solution Approach 2:
The patent uses tissue-specific host cell proteins as intermediaries to achieve selective enhancement of AAV transduction in target tissues. This mediator approach allows differential modulation of transduction efficiency across different tissue types, thereby maintaining tissue specificity while improving overall delivery effectiveness.
3Productivity
If host cell proteins are modulated to enhance AAV transduction, then transduction efficiency increases, but the complexity of the system increases
Solution Approach 1:
The patent leverages the cell's own host cell proteins to mediate AAV transduction enhancement. By modulating endogenous HCP expression rather than introducing external complex molecular machines, the patent achieves improved transduction efficiency while minimizing system complexity. The cellular machinery itself serves the function of enhancing transduction.
Solution Approach 2:
The patent simplifies the system by changing only the expression parameters of existing host cell proteins rather than introducing complex new components. This parameter-based approach to enhancing transduction efficiency avoids the complexity associated with structural modifications or additional molecular machinery.
Data Source
AI summary
The disclosure provides compositions and methods for modulating transduction efficiency of AAV particles. Specifically, the disclosure provides AAV transduction modulators that modulate genes or gene products associated with AAV transduction efficiency in gene therapies.